PREDICTORS OF PREGNANCY RATE IN ASSISTED REPRODUCTIVE TECHNOLOGIES: RESULTS OF THE IRIS OBSERVATIONAL PROGRAM IN THE POPULATION OF RUSSIA AND KAZAKHSTAN
Nazarenko T.A. Pestova T.I. Lokshin V.N. Dzhusubalieva T.M. Serov V.N. Baranov I.I. Bezhenar V.F. Gavisova A.A. Gorodnova E.A. Dolgushina N.V. Kalugina A.S. Kvashnina E.V. Kogan I.Y. Koloda Y.A. Korsak V.S. Krasnopolskaya K.V. Molchanova I.V. Sabirova V.L. Tapilskaya N.I. Sukhikh G.T.
2025Bionika Media Ltd.
Akusherstvo i Ginekologiya (Russian Federation)
2025#2025Issue 3144 - 158 pp.
Objective: To evaluate the predictors of in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI) success in females receiving oral dydrogesterone for luteal phase support with subsequent evaluation of the relationship between influencing factors and pregnancy rates, and the creation for the first time of a prognostic table for clinical pregnancy in IVF and ICSI cycles, identifying the most influential predictors. Materials and methods: Multicenter open-label observational program for assessing the probability of pregnancy in IVF cycles enrolled females who were prescribed dydrogesterone 30 mg a day for luteal phase support while undergoing assisted reproductive technology in routine setting of Russia and Kazakhstan according to the national guidelines. The primary objective of the study was to evaluate the predictors of pregnancy rate in IVF and ICSI, followed by the creation of a prognostic table of clinical pregnancy in IVF and ICSI cycles considering 4–5 most significant predictors. Secondary objectives assessed included biochemical and clinical pregnancy rates, convenience and overall satisfaction with therapy, live birth, and maternal and fetal safety were also assessed. Results: 1150 patients were enrolled from 42 study sites in the Russian Federation and 2 study sites in the Republic of Kazakhstan. 1146/1150 (99.7%) patients were exposed to Duphaston and constituted the safety set, out of them 534 patients were from the IVF subgroup, and 612 patients were from the ICSI subgroup. 1143/1150 (99.4%) patients constituted the full analysis set (994 from Russia and 149 from Kazakhstan) with a median age of 34 years. Clinical pregnancy rate was 36.7% and the live birth rate was 30.1%. The collected data has been used to build a clinical pregnancy rate prediction model. According to the prediction model, the best pregnancy probability while taking dydrogesterone would be for females under 37 years of age with antral follicle count of ≤12 and top-quality embryos, for whom IVF would be used. The study confirmed a high level of satisfaction with dydrogesterone therapy. In the study population dydrogesterone showed a favorable safety profile for fetus/newborn and mothers. Conclusion: Results of the study provide the practical a robust predictive model for IVF/ICSI success while demonstrating favorable oral dydrogesterone efficacy and safety profiles in routine practice.
assisted reproductive technology , dydrogesterone , ICSI , in vitro fertilization , intracytoplasmic sperm injection , IVF , predictive model
Text of the article Перейти на текст статьи
Academician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia, Moscow, Russian Federation
Regional Perinatal Center, Chelyabinsk, Russian Federation
National Academy of Sciences of the Republic of Kazakhstan, Almaty, Kazakhstan
International Academy of Reproductology, Almaty, Kazakhstan
PERSONA International Clinical Center for Reproductology, Almaty, Kazakhstan
Institute of Reproductive Medicine, Almaty, Kazakhstan
I.P. Pavlov First St. Petersburg State Medical University, Ministry of Health of Russia, St. Petersburg, Russian Federation
IVF Center Partus Clinic, Yekaterinburg, Russian Federation
D.O. Ott Research Institute of Obstetrics, Gynecology and Reproductology, St. Petersburg, Russian Federation
Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia, Moscow, Russian Federation
Life Line Reproduction Center, Moscow, Russian Federation
International Center for Reproductive Medicine, St. Petersburg, Russian Federation
Academician V.S. Krasnopolsky Moscow Regional Research Institute of Obstetrics and Gynecology, Moscow, Russian Federation
Prior Clinic LLC, Moscow, Russian Federation
Altai Regional Clinical Perinatal Center, Barnaul, Russian Federation
Institute of Fundamental Medicine and Biology, Kazan Federal University, Kazan, Russian Federation
Reproductive clinic Scandinavia (AVA-Kazan), Kazan, Russian Federation
Academician V.I. Kulakov National Medical Research Center for Obstetrics
Regional Perinatal Center
National Academy of Sciences of the Republic of Kazakhstan
International Academy of Reproductology
PERSONA International Clinical Center for Reproductology
Institute of Reproductive Medicine
I.P. Pavlov First St. Petersburg State Medical University
IVF Center Partus Clinic
D.O. Ott Research Institute of Obstetrics
Russian Medical Academy of Continuing Professional Education
Life Line Reproduction Center
International Center for Reproductive Medicine
Academician V.S. Krasnopolsky Moscow Regional Research Institute of Obstetrics and Gynecology
Prior Clinic LLC
Altai Regional Clinical Perinatal Center
Institute of Fundamental Medicine and Biology
Reproductive clinic Scandinavia (AVA-Kazan)
10 лет помогаем публиковать статьи Международный издатель
Книга Публикация научной статьи Волощук 2026 Book Publication of a scientific article 2026